Abstract: Asthma is a common heterogeneous disease, which often starts at a young age and has a reversible airway obstruction as its hallmark. Phenotypic differences in children with asthma may influence concomitant diseases and treatment choices. Despite the availability of effective drugs, asthma is poorly controlled in many children, which gives doctors the power to increasingly customize therapy from a personalized medicine perspective. The Global Initiative for Asthma (GINA) 2023 preserves and develops the agebased approach to diagnosis verification and therapy choice, which is supported in the All-Russia national program: Bronchial Asthma in Children and in the national clinical guidelines on bronchial asthma. Three age groups of patients were identified: zero to five years, six to eleven years and 12 years and older. Leukotriene receptor antagonists (in particular, montelukast) are often used in paediatric practice in children with asthma. The current guidelines show that leukotriene receptor antagonists (montelukast) are an alternative to inhaled glucocorticoids in mild, intermittent and persistent asthma. This is the first mediator-specific therapy for bronchial asthma. The best strategy in prescribing this group of drugs is to assess the severity of asthma, age and presence of concomitant diseases in children. The article uses clinical examples to discuss approaches to the asthma treatment with montelukast. The lack of asthma control tools results in high morbidity, mortality and costs of treatment, which justifies the search for new therapeutic options to improve control and reduce the risk of future exacerbations. ; Астма – распространенное гетерогенное заболевание, часто начинающееся в раннем возрасте и характеризующееся обратимой обструкцией дыхательных путей. Фенотипические различия, существующие у детей с астмой, могут влиять на сопутствующие заболевания и выбор терапии. Несмотря на доступность эффективных лекарств, у многих детей астма не контролируется должным образом, что требует от врача все чаще ...
Relation: https://www.med-sovet.pro/jour/article/view/7828/6949; Батожаргалова БЦ, Мизерницкий ЮЛ, Подольная МА. Метаанализ распространенности астмоподобных симптомов и бронхиальной астмы в России (по результатам программы ISAAC). Российский вестник перинатологии и педиатрии. 2016;61(4):59–69. https://doi.org/10.21508/1027-4065-2016-61-4-59-69.; Геппе НА, Колосова НГ, Кондюрина ЕГ, Малахов АБ, Ревякина ВА. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». 6-е изд. М.: МедКом-Про; 2021. 228 с.; Reddel HK, Yorgancıoğlu A (eds.). 2023 GINA Report, Global Strategy for Asthma Management and Prevention. 246 p. Available at: https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS.pdf.; Чучалин АГ, Авдеев СН, Айсанов ЗР, Белевский АС, Васильева ОС, Геппе НА и др. Бронхиальная астма: клинические рекомендации. М.; 2021. 104 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/359_2.; Pijnenburg MW, Baraldi E, Brand PL, Carlsen KH, Eber E, Frischer T et al. Monitoring asthma in children. Eur Respir J. 2015;45(4):906–925. https://doi.org/10.1183/09031936.00088814.; Szefler SJ, Fitzgerald DA, Adachi Y, Doull IJ, Fischer GB, Fletcher M et al. A worldwide charter for all children with asthma. Pediatr Pulmonol. 2020;55(5):1282–1292. https://doi.org/10.1002/ppul.24713.; Shipp CL, Gergen PJ, Gern JE, Matsui EC, Guilbert TW. Asthma Management in Children. J Allergy Clin Immunol Pract. 2023;11(1):9–18. https://doi.org/10.1016/j.jaip.2022.10.031.; Fitzpatrick AM, Jackson DJ, Mauger DT, Boehmer SJ, Phipatanakul W, Sheehan WJ et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–1618.e12. https://doi.org/10.1016/j.jaci.2016.09.028.; Геппе НА, Кондюрина ЕГ, Ревякина ВА, Малахов АБ, Колосова НГ. Терапия бронхиальной астмы у детей: возрастные аспекты. Педиатрия. Consilium Medicum. 2021;(2):113–122. https://doi.org/10.26442/26586630.2021.2.200928.; Мизерницкий ЮЛ. Антилейкотриены в терапии бронхиальной астмы у детей. Ожидаемые и реальные успехи. Медицинский совет. 2014;(14): 46–49. Режим доступа: https://www.med-sovet.pro/jour/article/view/1237/.; Trinh HKT, Lee SH, Cao TBT, Park HS. Asthma pharmacotherapy: an update on leukotriene treatments. Expert Rev Respir Med. 2019;13(12):1169–1178. https://doi.org/10.1080/17476348.2019.1670640.; Maroteau C, Espuela-Ortiz A, Herrera-Luis E, Srinivasan S, Carr F, Tavendale R et al. LTA4H rs2660845 association with montelukast response in early and late-onset asthma. PLoS ONE. 2021;16(9):e0257396. https://doi.org/10.1371/journal.pone.0257396.; Tamada T, Ichinose M. Leukotriene Receptor Antagonists and Antiallergy Drugs. In: Page C, Barnes P (eds.). Pharmacology and Therapeutics of Asthma and COPD. Handbook of Experimental Pharmacology. Vol. 237. Springer, Cham; 2016, pp. 153–169. https://doi.org/10.1007/164_2016_72.; Massingham K, Fox S, Smaldone A. Asthma therapy in pediatric patients: a systematic review of treatment with montelukast versus inhaled corticosteroids. J Pediatr Health Care. 2014;28(1):51–62. https://doi.org/10.1016/j.pedhc.2012.11.005.; Stanford RH, Shah M, Chaudhari SL. Clinical and economic outcomes associated with low-dose fluticasone propionate versus montelukast in children with asthma aged 4 to 11 years. Open Respir Med J. 2012;6:37–43. https://doi.org/10.2174/1874306401206010037.; Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatr Pulmonol. 2018;53(12):1670–1677. https://doi.org/10.1002/ppul.24176.; Колосова НГ, Шахназарова МД. Рациональный подход к терапии бронхиальной астмы у детей: что мы можем сделать для контроля заболевания? Медицинский совет. 2020;(1):140–144. https://doi.org/10.21518/2079-701X-2020-1-140-144.; Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. https://doi.org/10.1016/j.jaci.2017.03.050.; Астафьева НГ, Баранов АА, Вишнева ЕА, Дайхес НА, Жестков АВ, Ильина НИ и др. Аллергический ринит: клинические рекомендации. М.; 2020. 70 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/261_1.; Хаитов МР, Намазова-Баранова ЛС, Ильина НИ, Курбачева ОМ, Bachert C, Hellings PW и др. ARIA 2019: алгоритмы оказания помощи при аллергическом рините в России. Российский аллергологический журнал. 2020;17(1):7–22. https://doi.org/10.36691/RAJ.2020.17.1.001.; Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. https://doi.org/10.1002/alr.22073.; Seresirikachorn K, Chitsuthipakorn W, Kanjanawasee D, Khattiyawittayakun L, Snidvongs K. Leukotriene Receptor Antagonist Addition to H1-Antihistamine Is Effective for Treating Allergic Rhinitis: A Systematic Review and Meta-analysis. Am J Rhinol Allergy. 2019;33(5):591–600. https://doi.org/10.1177/1945892419844459.; Watts K, Chavasse RJ. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev. 2012;(5):CD006100. https://doi.org/10.1002/14651858.CD006100.pub2.; Dixon EG, Rugg-Gunn CE, Sellick V, Sinha IP, Hawcutt DB. Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review. BMJ Paediatr Open. 2021;5(1):e001206. https://doi.org/10.1136/bmjpo-2021-001206.; https://www.med-sovet.pro/jour/article/view/7828
_0.png)
Processing Request
No Comments.